Lead Product(s) : S1p receptor agonist 1
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CBP-307 (icanbelimod) is an once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 (S1P1) modulator in development for the treatment of ulcerative colitis (UC).
Brand Name : CBP-307
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 01, 2023
Lead Product(s) : S1p receptor agonist 1
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?